Kseniya Simpson
Principal at Hatteras Venture Partners
Raleigh-Durham-Chapel Hill Area
Overview
Work Experience
Principal
2024 - Current
Associate
2022 - 2024
Senior Analyst
2021 - 2022
Analyst
2019 - 2020
Venture Capital Multiplier Fund is a venture capital firm
Board Director
2025
Board Observer
2022 - 2025
Trefoil is a biotechnology company that brings forward novel engineered FGF-1 compounds to treat endothelial cell mediated diseases.
Raised $85,775,048.00 from Hatteras Venture Partners, Bios Partners, Correlation Ventures, Hatteras Venture Partners, Aju IB Investment, InFocus Capital Partners, Access Biotechnology and ExSight Ventures.
Board Observer
2023
Board Observer
2022
Aer Therapeutics, a clinical-stage biopharmaceutical company developing therapeutic solutions for muco-obstructive lung diseases.
Raised $36,000,000.00 from Hatteras Venture Partners, Canaan Partners and OrbiMed.
Board Observer
2022
Code Biotherapeutics is a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies.
Raised $85,000,000.00 from UPMC Enterprises, Amgen Ventures, CureDuchenne Ventures, New Enterprise Associates, 4BIO Capital, UCB Ventures, Takeda Ventures, JDRF T1D Fund, Northpond Ventures and Hatteras Venture Partners.
Board of Directors
2021
Board Observer
2020 - 2022
NASDAQ: VIGL IPO: 01/2022
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
Raised $180,000,000.00 from Sanofi.
Strategy Consultant
2017 - 2018
Associate Strategy Consultant
2016 - 2017
Postdoctoral Fellow
2015 - 2015
Laboratory of Dr. Joseph DeSimone (currently Professor of Translational Medicine and Chemical Engineering at Stanford University)
Licensing Intern
2013 - 2015